Therapeutic antibody development company Patrys Ltd (ASX:PAB) has provided an update on the recently completed GMP manufacturing run of PAT-DX1. Patrys’ contract development manufacturing organisation ...
Monoclonal antibodies -- treatments developed by cloning a cell that makes an antibody -- could help provide an answer to the growing problem of antimicrobial resistance, say scientists.